A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of AK120 in Subjects With Atopic Dermatitis

Inclusion Criteria:

1. Male or female with age 18 - 75 years (inclusive).

2. Atopic dermatitis (AD) diagnosed at least half an year before screening.

3. Subject with EASI score ≥16, IGA ≥ 3, BSA ≥ 10% at screening and baseline.

4. Subjects with a history of an inadequate response or medically inappropriate use oftopical drug treatment within 6 months.

Exclusion Criteria:

1. Suffering from other inflammatory diseases that may affect efficacy outcomes (suchas rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease,scleroderma, inflammatory myopathy, mixed connective tissue disease, overlapsyndrome, etc.).

2. History of exposure to active TB, and/or history or current evidence of TBinfection.

3. Positive serology results at Screening for hepatitis B, hepatitis C or HIV.

4. Any history of vernal keratoconjunctivitis (VKC) or atopic keratoconjunctivitis (AKC) within 6 months before the baseline visit.

5. History of clinical parasite infection, recent or planned travel to an area withendemic parasite infection within 6 months before the Screening visit

6. Any medical or psychiatric condition, laboratory, or ECG parameter which, in theopinion of the Investigator or the Sponsor's medical monitor, would place thesubject at risk, interfere with participation in the study, or interfere with theinterpretation of study results.